CD274 and cancer: When CPS ≥ 10 was used as a cut-off, the prevalence of PD-L1 positive cancers was 37% (281/763 patients) in the randomized KEYNOTE-062 study of advanced gastric or gastroesophageal junction cancers (Chao et al. 2021) and 18% (108/592 patients) in the randomized phase 3 KEYNOTE-061 trial (Fuchs et al. 2022).